Tissue connection device for percutaneous treatment for mitral regurgitation

Abstract

The invention provides a tissue connection device for percutaneous treatment for mitral regurgitation. The device comprises an elongated treatment conduit, a far end of which is suitable for piercing a tissue, a plurality of anchors capable of being closed up or expanded, at least one connection line suitable for a serial connection with a plurality of anchors, an elongated conveying shaft configured to pass through a cavity of the treatment conduit to convey the plurality of anchors in a serial connection with the at least one connection line to a target position from the far end of the treatment conduit one by one, wherein the plurality of anchor members are configured to be coaxially installed on the conveying shaft at a close-up state, accommodated in the cavity of the treatment conduit, and expanded after output from the far end of the treatment conduit. The tissue connection device enables the plurality of conveyed anchors to be coaxially accommodated in the treatment conduit, so the anchors can be precisely pushed out and anchored and seamed one by one surrounding a circular surface of a mitral valve; the anchors can be accurately conveyed to any positions and the circular surface wall can be well tightened; and mitral valve radius can be effectively reduced.

Description

technical field [0001] The invention relates to a tissue connection device for percutaneous treatment of mitral valve regurgitation. Background technique [0002] Mitral regurgitation (MR) is the most common valve disease in clinic. Etiologies of MR include rheumatic, degenerative, endocarditis, congenital, ischemic, or functional problems. [0003] MR is a common complication after acute myocardial infarction (AMI), and it is estimated that about 20% of patients with segmental left ventricular wall motion abnormality suffer from MR. Patients with congestive heart failure (CHF) are particularly prone to ischemic or functional MR. It is estimated that approximately 15% of CHF patients suffer from clinically severe MR, implying approximately 3 million CHF patients with MR worldwide. [0004] Numerous existing studies have confirmed the effectiveness of mitral valve repair for patients with different degrees of MR. [0005] In the past, patients with functional or ischemic ...

AI Technical Summary

Problems solved by technology

[0009] However, the anchors of such tissue-connecting devices are connected to each other by sutures, which cannot ensure that these anchors are coaxially and concentrically accommodated in the inner cavity of the delivery assembly. It is difficult to precisely control the anchor to push out from the jacket, pierce the tissue and perform anchoring, and it is also difficult to control the position of the anchor during anchoring, and it is easy to deviate from the position where the anchor needs to be anchored, so the therapeutic effect on the mitral valve is not enough ideal

Images